Drug class
Antisense oligonucleotide; investigational inhibitor of insulin receptor substrate-1 (IRS-1) expression
Mechanism of action
A synthetic antisense oligonucleotide designed to hybridise to IRS-1 mRNA, reducing expression of insulin receptor substrate-1 and downstream pro-angiogenic signalling involved in pathological corneal neovascularisation.
General use cases
- Investigational topical ophthalmic treatment studied for corneal neovascularisation, including neovascularisation associated with herpetic keratitis and high-risk corneal transplantation. Aganirsen remains investigational; it should not be presented as an approved routine therapy.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
